Hirsutism

Hair, Hair Growth and Hair Disorders

Volumn , Issue , 2008, Pages 357-377

  Camacho Martínez, Francisco M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 63049137285     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-46911-7_17     Document Type: Chapter

References (82)

1. Amichai B, Grunwald MH, Sobel R. (1997) 5a-reductase inhibitors - A new hope in dermatology? Int J Dermatol; 36:182-184.
2. Archer JS, Chang RJ.(2004) Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol; 18:737-754.
3. Barbieri RL, Gargiulo AR. (2004) Metformin for the treatment of the polycystic ovary syndrome. Minerva Ginecol; 56:63-79.
4. Bayram F, Muderris I, Guven M, Ozcelik, Kelestimur F. (2003) Low-dose (2.5 mg/day) finasteride treatment in hirsutism. Gynecol Endocrinol; 17:419-422.
5. Blume-Peytavi U, Gieler U, Hoffmann R, Lavery S, Shapiro J. (2007) Unwanted facial hair: Affects, effects and solutions. Dermatology; 215:139-146.
6. Bratoeff E, Cabeza M, Ramirez E, Heuze I, Flores E. (2005) Recent advances in the chemistry and pharmacological activity of new steroideal antiantrogen and 5α-reductase inhibitors. Curr Med Chem; 12:927-943.
7. Camacho F. Hirsutism. In: Camacho F, Montagna W, eds. (1997) Trichology. Diseases of the Pilosebaceus Follicle. Madrid: Aula Medica; 265-298.
8. Camacho F. (1997) SAHA syndrome. In: Camacho F, Montagna W, eds. Trichology. Diseases of the pilosebaceus follicle. Madrid: Aula Medica; 673-690.
9. Camacho F. (1999) SAHA syndrome: female androgenetic alopecia and hirsutism. Exp Dermatol; 8:304-305.
10. Camacho F. Constitutional hirsutism. The SAHA syndrome. In: Camacho F, Randall VA, Price VH, eds. (2000) Hair and its Disorders. Biology, Pathology and Management. London: Martin Dunitz; 359-367.
11. Camacho F. Drug treatment of hirsutism. In: Camacho F, Randall VA, Price VH, eds. (2000) Hair and its Disorders. Biology, Pathology and Management. London: Martin Dunitz; 369-381.
12. Camacho F. (2001) Hirsutismo. Enfoque clinico-Terapeutico I. Act Terap Dermatol (Arg); 24:96-108.
13. Camacho F. (2001) Hirsutismo. Enfoque clinico-Terapeutico II. Act Terap Dermatol (Arg); 24:190-206.
14. Camacho F. (2003) Hypertrichosis and hirsutism. In: Bolognia J, Jorizzo JL, Rapini RP, eds. Dermatolopgy, 1st edn. London: Mosby; 1051-1059.
15. Camacho F. (2006) Tratamiento del hirsutismo. Actas Dermosifiliogr; 97 (Suppl. 1); 33-44.
16. Camacho F. La perdida de cabello en la mujer. In: Grimalt R, ed. (2006) Cuidemos de nuestro pelo. Barcelona: Farmalia Comunicacion; 61-103.
17. Camacho FM, Goldberg NG. (2000) Laser. Introduccion. Presente y futuro. In: Cisneros Vela JL, Camacho FM, eds. Laser y fuentes de luz pulsada intensa en dermatologia y dermocosmetica. Madrid: Aula Medica; 1-25.
18. Camacho F, Munoz MA. (1996) HAIRAN syndrome. In: Van Neste D, Randall V, eds. Hair Research for the Next Millennium. Amsterdam: Elsevier; 289-292.
19. Camacho F, Ortega del Olmo RM. (2007) Hirsutismo. Monogr Dermatol; 20:293-309.
20. Camacho F, Sanchez-Pedreno P. (1993) Espironolactona en el tratamiento del sindrome SAHA. Med Cut Iber Lat Am; 21:07-114.
21. Camacho F, Tosti A. (2005) Tratamiento medico de las alopecias femeninas. Monogr Dermatol; 18:92-117.
22. Carmina E, Lobo RA. (1997) Gonadotropin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum Reprod; 12:663-666.
23. Castello R, Tosti F, Perrone F. (1996) Outcome of longterm treatment with 5-Alpha-reductase inhibitor finasteride in idiopathic hirsutism. Clinical and hormonal effects during 1 year course of therapy and 1 year follow up. Fertil Steril; 66:734-740.
24. Colao A, Lombardi G, Annunziato L. (2000) Cabergoline. Exp Opin Pharmacother; 1:555-574.
25. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. (1994) Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil Steril; 61:281-287.
26. Dawber R, Sinclair R. (2001) Hirsuties. Clin Dermatol; 19:189-199.
27. De Berker D. (2000) Clinical features of hirsutism: variations with age and race. In: Camacho F, Randall VA, Price VH, eds. Hair and its Disorders. Biology, Pathology and Management. London: Martin Dunitz; 351-7.
28. DeGrott LJ, Jameson JL. (2006) Adrenal glands and adrenal hormones. In: DeGrott LJ, Jameson JL, eds. Endocrinology. Amsterdam: Elsevier Saunders; 2394.
29. Dodin S, Faure N, Cedrin I. (1995) Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin Endocrinol; 43:575-582.
30. Escobar-Morreale HF, Serrano-Gotarredona J, Avila S, Villar-Palasi J, Varela C, Sancho J. (1998) The increased circulating prostate specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab; 83:2580-2584.
31. Falsetti L, Gambera A. (1999) Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism. Fertil Steril; 72:41-46.
32. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. (1999) Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrino; 141:361-367.
33. Falsetti L, Gambera A, Platto CH, Legrenzi L. (2000) Management of hirsutism. Am J Clin Dermatol; 1:89-99.
34. Ferriman D, Gallwey JD. (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab; 21:1440-1447.
35. Flores E, Bratoeff E, Cabeza M, Ramirez E, Quiroz A, Heuze I. (2003) Steroid 5α-reductase inhibitors. Mini Rev Med Chem; 3:225-237.
36. Fruzzetti F, de Lorenzo D, Parrini D. (1994) Finasteride (Proscar) reduces hair growth in hirsute women without affecting gonadotropin secretion. J Clin Endocrinol Metab; 79:831-835.
37. Galadari I, Al-Mazroei M, Alkaabi J. (2004) Prostaticspecific antigen and idiopathic hirsutism in females. Int J Dermatol; 43:275-277.
38. Garcia Hernandez MJ. (2006) Hirsutismo ovarico y otros hirsutismos. Actas Dermosifiliogr; 97 (Suppl. 1):27-38.
39. Gullu S, Emral R, Asik M, Cesur M, Tonyukuk V. (2003) Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Invest; 26:1198-1202.
40. Gupta AK, Knowles SR, Shear NH. (1994) Spironolactone associated cutaneous effects: A case report and a review of the literature. Dermatology; 189:402-405.
41. Hammerstein J. (1990) Antiandrogens: clinical aspects. In: Orfanos CE, Happle R, eds. Hair and Hair Diseases. Berlin: Springer; 827-886.
42. Hamzavi I, Tan E, Shapiro J, Lui H. (2007) A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol; 57:54-59.
43. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. (2003) Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab; 88:4116-4123.
44. Harborne LR, Sattar N, Norman JE, Fleming R. (2004) Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 4; 90:4593-4598.
45. Hart R, Kickey M, Franks S. (2004) Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol; 18:671-683.
46. Hatwall A, Bhatt RP, Agrawal JK, Singh G, Bajpai HS. (1988) Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol; 68:84-87.
47. Ibanez L, Potau N, Marcos MV, de Zegher F. (2000) Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide. J Clin Endocrinol Metab; 85:3251-3255.
48. Inoue A, Teramae H, Hisa T, Taniguchi S, Chanoki M, Hamada T. (1995) Fixed drug eruption due to cimetidine. Acta Derm Venereol; 75:250.
49. Kazerooni T, Dehghan-Kooshkghazi M. (2003) Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol; 17:51-56.
50. Lanham MSM, Lebovic DI, Domino SE. (2006) Contemporary medical therapy for polycystic ovary syndrome. Int J Gynecol Obst; 95:236-241.
51. Leyden J, Bergfeld W, Drake L, Dunlap F, et al. (2006) A systemic type I 5α-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol; 50:443-447.
52. Lowenstein EJ. (2006) Diagnosis and management of the dermatologic manifestation of the polycystic ovary syndrome. Dermatol Ther; 19:210-223.
53. Manetti L, Lupi I, Bogazzi F, Pellegrini G, Precisi A, Grasso I, Nencetti C, Gasperi M, Martino E. (2002) Prostate-specific antigen is increased in female patients with Cushing's disease. J Endocrinol Invest; 25:29-31.
54. Manetti L, Lupi I, Genovesi M, Morselli L, Grasso I, Nencetti C, Gasperi M, Bogazzi F, Bartelena L, Martino E. (2004) Serum prostate-specific antigen concentration is increased in acromegalic women. J Endocrinol Invest; 27:643-647.
55. Martin-Hernandez T, Jorquera E, Torres A, Camacho F, Herrera E. (1995) Comparacion de la eficacia de la flutamida y el acetato de ciproterona en el tratamiento del hirsutismo asociado al sindrome de los ovarios poliquisticos. Actas Dermosifiliogr; 86:327-334.
56. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo, Castello R. (2000) Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab; 85:89-94.
57. Morcos RN, Abdul-Malak ME, Shikora E. (1994) Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy. Fertil Steril; 61:427-431.
58. Moreno Gimenez JC, Galan Gutierrez M. (2006) Hirsutismo suprarrenal. Actas Dermosifiliogr; 97 (Suppl. 1):17-26.
59. Muderris II, Bayram F, Guven M. (2000) Treatment of hirsutism with lowest-dose flutamide (62. 5mg/day). Gynecol Endocrinol; 14:38-41.
60. Negri C, Tosti F, Dorizzi R, Fortunato A, Spiazzi GG, Mugeo M, Castello R, Moghetti P. (2000) Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: Evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab; 85:81-84.
61. Nguyen QH, Chen T, Wang X, Chen Y, Chien P. (1995) Finasteride inhibits 5-A-reductase activity in human dermal fibroblasts: prediction of its therapeutic application in androgen-related diseases. Int J Dermatol; 34:720-724.
62. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS, (2006) Dutasteride Alopecia Research Team. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol; 55:1014-1023.
63. Olszewska M, Rudnicke L. (2005) Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol; 4:637-640.
64. Orfanos CE. (1982) Antiandrogenos en Dermatologia. Arch Arg Dermat; 32:52-55.
65. Orfanos CE, Adler YD, Zouboulis CC. (2000) The SAHA syndrome. Horm Res; 54:251-258.
66. Ortega del Olmo RM, Camacho FM. (2006) Hirsutismo idiopatico, constitucional o dermatologico. Actas Dermosifiliogr; 97 (Suppl. 1):8-16.
67. Paoletti AM, Cagnacci A, Orru M, Ajossa S, Guerreiro S, Melis GB. (1999) Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Fertil Steril; 72:448-453.
68. Pasquali R, Fabbri R, Venturoli S, Paradisi R, Antenucci D, Melchionda N. (1986) Effect of weight loss and antiandrogenic therapy on sex-hormone blood levelsand insulin resistance in obese patients with polycystic ovary syndrome. Am J Obstet Gynecol; 154:139-144.
69. Pazos F, Escobar-Morreale HF, Balsa J, Sancho JM, Varela C. (2000) Prospective randomized study comparing the long-Acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril; 71:122-128.
70. Randall VA. (2000) Androgens. The main regulator of human hair growth. In: Camacho F, Randall VA, Price VH, eds. Hair and its Disorders. Biology, Pathology and Management. London: Martin Dunitz; 70-82.
71. Richard RN, Meharg GE. (1995) Electrolysis: Observations from 13 years and 140, 000 hours of experience. J Am Acad Dermatol, 33:662-666.
72. Sam S, Legro RS, Essah PA, (2006) Apridonidze T, Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci USA; 103:7030-7035.
73. Schon MP, Tebbe B, Trautmann C, Orfanos CE. (1994) Lichenoid drug eruption induced by spironolactone. Acta Derm Venereol; 74:476.
74. Sperling LC, Heimer WL. (1993) Androgen biology as a basis for the diagnosis and treatment of androgenic disorders in women. I. J Am Acad Dermatol; 28:669-683.
75. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. (2000) Spironolactone as a single agent for long-Term therapy of hirsute patients. Clin Endocrinol (Oxf); 52:587-594.
76. Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, Chrousos GP. (1998) Skin manifestationbs of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia. Pediatr Dermatol; 15:253-258.
77. Tartagni M, Schonauer LM, Da Salvia MA, Cicinelli E, De Pergola G, D'Adario G. (2000) Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steri; 71:718-723.
78. Tartagni M, Schonauer MM, Cicinelli E, Petruzelli F, De Pergola G, De Silvia MA, Loverro G. (2004) Intermittent low-dose is as effective as daily administration for the treatment of hirsute women. Fertil Steril; 82:752-755.
79. Tolino A, Petrone A, Sarnacchiaro F. (1996) Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril; 66:61-65.
80. Toscano V, Adamo MV, Caiola S, Foli S, Petrangeli E, Cassilli D, Sciarra F. (1983) Is hirsutism an evolving syndrome? J Endocrinol; 97:379-387.
81. Wolf JE, Shander D, Huber F, Jackson J, Lin Ch-S, Mathes BM, Schroede K, and The Eflornithine HCI Study Group (2007). Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine 1HCI 13. 9% in the treatment of women with facial hair. Int J Dermatol; 46:94-98.
82. Zabala R, Gardeazabal J, Manzano D, Aguirre A, Zubizarreta J, Tuneu A, Diaz Perez JL (1995). Fotosensibilidad por flutamida. Actas Dermosifiliogr; 86:323-325.